<DOC>
	<DOCNO>NCT01814241</DOCNO>
	<brief_summary>The purpose study attempt understand desensitization work peanut allergic child undergo oral immunotherapy ( OIT ) peanut . We want identify early change desensitization process immune cell undergo become desensitized peanut protein .</brief_summary>
	<brief_title>Mechanisms Desensitization During Peanut Oral Immunotherapy</brief_title>
	<detailed_description>Peanut allergic child undergo oral food challenge ( OFC ) 1 gm peanut protein order accomplish two objective : ( 1 ) confirm diagnosis peanut allergy , ( 2 ) measure amount peanut protein take cause allergic reaction . Each subject undergo modify rush phase subject receive 6 dos peanut protein one day . The build-up phase begin afterward subject 's dose peanut protein increase every 2 week 36 week . After final build-up dose , subject consumes dose 2 week return food allergy center second food challenge . If subject successfully consumes food challenge without symptom , daily dose peanut protein stop subject undergo third food challenge . If subject successfully consume peanut protein challenge , return fourth food challenge peanut .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Food Hypersensitivity</mesh_term>
	<criteria>Age 4 12 year age gender , race , ethnicity . Minimum weight 16 kg time enrollment . Physician diagnosis peanut allergy OR convince clinical history allergic reaction peanut . Detectable serum peanut specific IgE level ( CAPFEIA ≥ 0.35 kU/L ) positive SPT ( wheal ≥ 3mm skin prick test peanut extract compare negative control . ) Allergic reaction ≤ 1 gm peanut protein blind oral challenge test conduct screening ( e.g. , doubleblinded , placebocontrolled food challenge [ DBPCFC ] ) . Written inform consent parent/guardian . Written assent subject applicable Consumption oatcontaining product within 90 day prior enrollment History allergic reaction peanut consistent severe anaphylaxis ( defined hypotension/shock ; neurologic impairment ) . Chronic disease asthma , atopic dermatitis , rhinitis require therapy ; e.g. , heart disease diabetes . Active eosinophilic gastrointestinal disease past 2 year Participation interventional study treatment food allergy 6 month prior visit 1 Inhalant allergen immunotherapy yet reach maintenance dosing . Asthma define moderate severe persistent National Asthma Education Prevention Program Expert Panel Guidelines ( e.g . asthma require fluticasone 440 mcg equivalent daily adequate control ) . Inability discontinue antihistamine skin test , OFC initial dose escalation . Use omalizumab nontraditional form allergen immunotherapy ( e.g. , oral sublingual ) 12 month prior visit 1 . Any systemic therapy judgment investigator could immunomodulatory ( e.g . rituximab ) 12 month prior visit 1 , Systemic corticosteroid therapy total three week allow . Use investigational drug 90 day prior visit 1 . Plan use investigational drug study period . The presence medical condition investigator deem incompatible participation trial . Inability speak English .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Peanut allergy</keyword>
</DOC>